UBTD2

Across TCGA pan-cancer cohorts, UBTD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBTD2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher UBTD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBTD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where UBTD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.613	0.928	<.001	59	view →
PDAC	DFS	Median	II,III,IV	0.614	0.911	<.001	19	view →
LUAD	DFS	Tertile	All	1.000	0.518	.006	13	view →
HNSC	DFS	Median	II,III,IV	0.775	0.546	.012	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UBTD2–LSCC (DFS)

Open the LSCC breakdown →